Ziten-M 500mg/20mg Tablet ER

Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, prolongs the activity of incretin hormones, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner, contributing to improved glycemic regulation. The extended-release formulation ensures a gradual release of active ingredients, minimizing gastrointestinal side effects commonly associated with Metformin and enhancing patient compliance through once-daily dosing.

Ziten-M is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, particularly when monotherapy with Metformin alone is insufficient. It is essential to monitor renal function prior to and during therapy due to Metformin’s renal clearance. Contraindications include severe renal impairment, metabolic acidosis, and hypersensitivity to components.

Regular monitoring of blood glucose and HbA1c levels is recommended to assess therapeutic efficacy and adjust dosage accordingly.